乳腺癌经新辅助化疗后锁骨上淋巴结病理完全缓解与预后的关联性

Analysis on the Correlation Between Pathological Remission and Prognosis of Supraclavicular Lymph Nodes with Neoadjuvant Chemotherapy in Breast Cancer

目的探讨乳腺癌经新辅助化疗后锁骨上淋巴结病理完全缓解(spCR)与预后的关联性。方法回顾性分析186例伴同侧锁骨上淋巴结转移(ISINM)乳腺癌患者临床资料,分析影响伴ISINM乳腺癌患者无病生存率的相关影响因素,分析spCR对乳腺癌患者无复发生存(DFS)的影响。结果186例患者经新辅助化疗干预后获得spCR 98例(52.69%),出现转移或复发72例(38.71%);spCR是影响伴ISINM乳腺癌患者无病生存率的独立因素(P<0.05且OR>1);获得spCR患者的中位DFS为67.4个月(95%CI:53.09~81.47),高于未获得spCR患者的25.3个月(95%CI:21.48~29.32),差异有统计学意义(P<0.05)。结论乳腺癌经新辅助化疗干预后获得spCR的患者预后优于未获得spCR患者,其可影响患者的无病生存率,预测DFS。

Objective To investigate the relationship between spCR and prognosis of breast cancer with neoadjuvant chemotherapy intervention in supraclavicular lymph node pathology.Methods The clinical data of 186 cases of breast cancer with ipsilateral supraclavicular lymph node metastasis(ISINM)were retrospectively analyzed,Analysis of factors affecting disease-free survival in patients with ISINM breast cancer,To analyze the effect of spCR on survival(DFS)without recurrence in breast cancer patients.Results 186 patients received spCR 98 cases after neoadjuvant chemotherapy intervention(52.69%),Metastasis or recurrence occurred in 72 cases(38.71%);spCR is a high risk factor for disease-free survival in patients with ISINM breast cancer(P<0.05 and OR>1);The median DFS of spCR patients was 67.4 months(95%CI:53.09-81.47),More than 25.3 months for patients without spCR(95%CI:21.48-29.32),difference was statistically significant(P<0.05).Conclusion The prognosis of breast cancer spCR neoadjuvant chemotherapy is better than that of spCR patients,It can affect patient survival,DFS.of projections.